Sandostatin Lar Depot Kit
Product Images NDC 0078-0818

4 FDA label images from Novartis Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sandostatin Lar Depot (NDC 0078-0818). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Octreotide Amino Acid Sequence (Sandostatinlar 01)

Octreotide Amino Acid Sequence (Sandostatinlar 01)
Chemical structure of octreotide acetate showing the cyclic peptide sequence with amino acid residues and the acetate ion represented as CH3COOH with variable x from 1.4 to 2.5.*
FDA Label Image

Principal Display Panel Ndc 0078-0811-81 Sandostatin® Lar Depot (octreotide Acetate) For Injectable Suspension, For Gluteal Intramuscular Use 10 mg For Intragluteal Injection Rx Only Novartis (Sandostatinlar 02)

Principal Display Panel Ndc 0078-0811-81 Sandostatin® Lar Depot (octreotide Acetate) For Injectable Suspension, For Gluteal Intramuscular Use 10 mg For Intragluteal Injection Rx Only Novartis (Sandostatinlar 02)
Packaging label for Sandostatin LAR Depot 10 mg kit, an injectable suspension of octreotide acetate intended for gluteal intramuscular injection. The label includes product name, strength, dosage form (kit), instructions for reconstitution, contents of the kit, and Novartis Pharmaceuticals Corporation as the labeler. The label also displays barcode and regulatory information.*
FDA Label Image

Principal Display Panel Ndc 0078-0818-81 Sandostatin® Lar Depot (octreotide Acetate) For Injectable Suspension, For Gluteal Intramuscular Use 20 mg For Intragluteal Injection Rx Only Novartis (Sandostatinlar 03)

Principal Display Panel Ndc 0078-0818-81 Sandostatin® Lar Depot (octreotide Acetate) For Injectable Suspension, For Gluteal Intramuscular Use 20 mg For Intragluteal Injection Rx Only Novartis (Sandostatinlar 03)
Packaging label for Sandostatin LAR Depot 20 mg kit containing octreotide acetate for injectable suspension, intended for gluteal intramuscular use. The label shows the product name, strength, dosage form (kit), and indicates prescription only. Labeler is Novartis Pharmaceuticals Corporation. Includes instructions and contents of the kit, including vial and prefilled syringe for reconstitution.*
FDA Label Image

Principal Display Panel Ndc 0078-0825-81 Sandostatin® Lar Depot (octreotide Acetate) For Injectable Suspension, For Gluteal Intramuscular Use 30 mg For Intragluteal Injection Rx Only Novartis (Sandostatinlar 04)

Principal Display Panel Ndc 0078-0825-81 Sandostatin® Lar Depot (octreotide Acetate) For Injectable Suspension, For Gluteal Intramuscular Use 30 mg For Intragluteal Injection Rx Only Novartis (Sandostatinlar 04)
Packaging label for Sandostatin LAR Depot 30 mg kit, an injectable suspension containing octreotide acetate, intended for gluteal intramuscular use. The label includes instructions for intragluteal injection, contents of the kit, and cautions related to reconstitution. The product is labeled for prescription use only and manufactured by Novartis Pharmaceuticals Corporation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.